Growth inhibition of human melanoma cells by a recombinant arginine deiminase expressed in Escherichia coli.

Abstract

We have cloned the arginine deiminase (ADI) gene from Mycoplasma hominis PG21 genomic DNA by polymerase chain reaction, and changed four TGA tryptophan codons (stop codon in E. coli) to TGG codons in the coding region by site-directed mutagenesis in order to express in E. coli. The recombinant ADI (rADI) was purified to apparent homogeneity by Ni-affinity chromatography after extraction from inclusion bodies followed by refolding. The rADI expressed in E. coli was estimated to be 50 kDa. Dimeric forms of rADI exerted enzymatic activity. We found that high concentration of potassium dihydrogenphosphate (PDP) and L-arginine addition in refolding reaction increases the enzyme activity. The specific activity of rADl was calculated as 0.618 U/mg. In addition, the enzyme activity of purified rADI remained for at least one month in 100 mM PDP solution (pH 6.5), but diminished within one week in 100 mM PDP solution (pH 7.4). Anti-tumor activity of the purified rADI was estimated to be 0.036 U/ml as 50% growth inhibitory activity against human melanoma cell line G-361.

• Authors: Megumi Kozai, Eriko Sasamori, Masatoshi Fujihara, Tetsuro Yamashita, Hideharu Taira, Ryô Harasawa
• Journal: The Journal of veterinary medical science (J Vet Med Sci) Vol. 71 Issue 10 Pg. 1343-7 (Oct 2009) ISSN: 0916-7250 [Print] Japan
• PMID: 19887741 (Publication Type: Journal Article)

Chemical References

• Antineoplastic Agents
• Recombinant Proteins
• Hydrolases
• arginine deiminase

Topics

• Antineoplastic Agents (pharmacology)
• Cell Line, Tumor
• Cloning, Molecular
• Escherichia coli (genetics, metabolism)
• Gene Expression Regulation, Bacterial
• Gene Expression Regulation, Enzymologic
• Humans
• Hydrolases (chemistry, genetics, metabolism, pharmacology)
• Melanoma (metabolism)
• Mycoplasma hominis (enzymology)
• Recombinant Proteins